drugset / Trial / NCT07568678
A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes
RandomizedSequentialDouble-blindTreatment
Summary
The study is to assess the safety, pharmacokinetics, and pharmacodynamic profile of HMS1005 in patient with diabetes
Timeline
- Start
- 2025-12-04
- Primary completion
- 2026-08-13
- Completion
- 2026-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMS1005 | Unknown | 123 mg | — |
| Subject | HMS1005 | Unknown | 184.5 mg | — |
| Subject | HMS1005 | Unknown | 246 mg | — |
| Subject | HMS1005 | Unknown | 369 mg | — |
| Subject | HMS1005 | Unknown | 492 mg | — |